Belantamab Mafodotin Tops Daratumumab in Multiple Myeloma Belantamab Mafodotin Tops Daratumumab in Multiple Myeloma

The phase 3 study findings supported belantamab mafodotin as a potential new standard of care in the second line or later among patients with released/refractory multiple myeloma.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news